. SEC profiles of the NMR samples of the α4β2-TMDs eluted with buffer containing (A) 0.05% LDAO and (B) 1.1% LDAO. The same position of the dominant protein peak in (A) and (B) suggests that the protein is eluted as pentamers at high and low LDAO concentrations.
N TROSY-HSQC spectra of the (α4) 3 (β2) 2 -TMD (only the α4-TMD is 15 N-labeled and visible) in the absence (red) and the presence (green) of 15 μM (S)-(+)-mecamylamine showing the drug effect on the α4-TMD residues. One-letter amino acid code followed by the TMD sequence number is used for the chemical shift assignment. The α4-residues (using the full-length α4 subunit sequence) sensitive to the drug are marked by ovals and include Leu235 (L27), Val236 (V28), and Leu239 (L31) (at TM1), and Gly244 (G36), Thr248 (T40), and Leu249 (L41) (at TM2).
Fig. S3.
Overlay of 1 H-15 N TROSY-HSQC spectra of the (α4) 2 (β2) 3 -TMD (only the β2-TMD is 15 N-labeled and visible) in the absence (red) and the presence (green) of 15 μM (S)-(+)-mecamylamine showing the drug effect on the β2-TMD residues. One-letter amino acid code followed by the TMD sequence number was used for the chemical shift assignment. The β2-residues (using the full-length β2 subunit sequence) sensitive to the drug are marked by ovals and include Val230 (V28) (at TM1), Gly238 (G36) and Lys260 (K58) (at TM2), Ile287 (I85) (at TM3), and Thr449 (T125) (at TM4). Note multiple conformations of Thr265(T63), which is at the M2-M3 loop. N TROSY-HSQC spectra of the (α4) 3 (β2) 2 -TMD (only the α4-TMD is 15 N-labeled and visible) in the absence (red) and the presence (green) of 15 μM (R)-(-)-mecamylamine showing the drug effect on the α4-TMD residues. One-letter amino acid code followed by the TMD sequence number was used for the chemical shift assignment. The α4-residues (using the full-length α4 subunit sequence) sensitive to the drug are marked by ovals and include Leu235 (L27), Val236 (V28), and Leu239 (L31) (at TM1), Gly244 (G36), Thr248 (T40), Glu266 (E58), and Ile268 (I60) (at TM2), and Thr296 (T88) (at TM3). N TROSY-HSQC spectra of the (α4) 2 (β2) 3 -TMD (only the β2-TMD is 15 N-labeled and visible) in the absence (red) and the presence (green) of 15 μM (R)-(-)-mecamylamine showing the drug effect on the β2-TMD residues. One-letter amino acid code followed by the TMD sequence number was used for the chemical shift assignment. The β2-residues (using the full-length β2 subunit sequence) sensitive to the drug are marked by ovals and include Val230 (V28) and Leu233 (L31) (at TM1), Lys240 (K38) (at TM2), and Ile287 (I85) (at TM3). Note multiple conformations of Thr265(T63), which is at the M2-M3 loop. . Data were obtained from the 1 H-15 N TROSY-HSQC spectra of the (α4) 3 (β2) 2 -and (α4) 2 (β2) 3 -TMDs in the absence and presence of 15 μM (R)-(-)-mecamylamine (see Fig. S6 and Fig. S7 ). (1/Δδ')(1+K d /C) for the selected residues: 3.2 ± 0.6 M for β2-K240 (K38), 2.2 ± 0.6 M for β2-V230 (V28), and 1.4 ± 0.4 M β2-I287 (I85). (B) Exponential decay of residue intensity as a function of (R)-(-)-mecamylamine concentration is demonstrated for residues α4-I268 (I60) and β2-V230 (V28).
